DK1167537T3 - Fremgangsmåde til fremstilling af et monoklonalt antistof - Google Patents
Fremgangsmåde til fremstilling af et monoklonalt antistofInfo
- Publication number
- DK1167537T3 DK1167537T3 DK00912975T DK00912975T DK1167537T3 DK 1167537 T3 DK1167537 T3 DK 1167537T3 DK 00912975 T DK00912975 T DK 00912975T DK 00912975 T DK00912975 T DK 00912975T DK 1167537 T3 DK1167537 T3 DK 1167537T3
- Authority
- DK
- Denmark
- Prior art keywords
- monoclonal antibody
- producing
- hybridoma
- immortalized
- cell
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8792999 | 1999-03-30 | ||
| PCT/JP2000/002022 WO2000058499A1 (fr) | 1999-03-30 | 2000-03-30 | Procede pour la production d'anticorps monoclonal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1167537T3 true DK1167537T3 (da) | 2008-11-10 |
Family
ID=13928616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00912975T DK1167537T3 (da) | 1999-03-30 | 2000-03-30 | Fremgangsmåde til fremstilling af et monoklonalt antistof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8236530B2 (fr) |
| EP (1) | EP1167537B1 (fr) |
| AT (1) | ATE402267T1 (fr) |
| AU (1) | AU754808B2 (fr) |
| CA (1) | CA2368734C (fr) |
| DE (1) | DE60039596D1 (fr) |
| DK (1) | DK1167537T3 (fr) |
| WO (1) | WO2000058499A1 (fr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| HUP0501113A3 (en) | 2001-04-26 | 2007-12-28 | Biogen Idec Inc | Cripto blocking antibodies and uses thereof |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| EP1603450A4 (fr) | 2003-03-07 | 2009-07-29 | Univ Columbia | Procedes utilisant le recepteur de la ryanodine de type 1 |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| EP1911766A1 (fr) * | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Utilisation des cellules humaines provenant d'une leucémie myéloide pour l'expression d'anticorps |
| ZA200901912B (en) * | 2006-09-10 | 2010-06-30 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| EP2073842B2 (fr) | 2006-09-10 | 2023-10-18 | Glycotope GmbH | Utilisation des cellules humaines provenant d'une leucémie myéloïde pour l'expression d'anticorps |
| AU2013203482B2 (en) * | 2006-09-10 | 2015-08-27 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
| US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| EP1920782A1 (fr) | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Microorganismes, ou fractions desdits microorganismes, capables d'induir de l' immunité cellulaire specifique contre des hydrates de carbone |
| JP2010518115A (ja) | 2007-02-09 | 2010-05-27 | ジェネンテック， インコーポレイテッド | 抗Ｒｏｂｏ４抗体およびそれらのための使用 |
| WO2008112193A1 (fr) | 2007-03-12 | 2008-09-18 | Dana-Farber Cancer Institute | Pronostic, diagnostic et utilisations dans le traitement du cancer de fanci et des agents de modulation de fanci |
| AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| SG176303A1 (en) | 2009-06-10 | 2012-01-30 | Stephen Sanig Res Inst Ltd | Methods of generating cells exhibiting phenotypic plasticity |
| WO2011014457A1 (fr) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Traitements dassociation |
| WO2011028950A1 (fr) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened et ses méthodes d'utilisation |
| US8486397B2 (en) | 2009-12-11 | 2013-07-16 | Genentech, Inc. | Anti-VEGF-C antibodies and methods using same |
| CN107095846A (zh) | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| US8481680B2 (en) | 2010-10-05 | 2013-07-09 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| AR095398A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida |
| US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
| CA2904166C (fr) | 2013-03-13 | 2021-05-18 | Genentech, Inc. | Formulations ayant une oxydation reduite |
| LT2968467T (lt) | 2013-03-13 | 2020-08-25 | F. Hoffmann-La Roche Ag | Sumažintos oksidacijos kompozicijos |
| RU2019120404A (ru) | 2013-03-13 | 2019-08-06 | Дженентек, Инк. | Составы антител |
| RU2015144020A (ru) | 2013-03-15 | 2017-04-21 | Дженентек, Инк. | Среды для культивирования клеток и способы получения антител |
| SG10201809452RA (en) | 2013-03-15 | 2018-11-29 | Genentech Inc | Cell culture compositions with antioxidants and methods for polypeptide production |
| EA201991715A1 (ru) | 2013-09-27 | 2020-03-31 | Дженентек, Инк. | Композиции, содержащие антитело к pdl1 |
| EP3083690A1 (fr) | 2013-12-17 | 2016-10-26 | F.Hoffmann-La Roche Ag | Méthodes de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-cd20 |
| US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3680254A1 (fr) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Procédés de traitement de cancers positifs her2 à l'aide d'antagonistes de liaison d'axe pd-1 et d'anticorps anti-her2 |
| CA2937539A1 (fr) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened et methodes d'utilisation de celui-ci |
| BR112016022345A2 (pt) | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
| EP3193932B1 (fr) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Formulations d'anticorps |
| MX2017006320A (es) | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| EP3253784B1 (fr) | 2015-02-04 | 2020-05-06 | Genentech, Inc. | Mutant smoothened et méthodes d'utilisation de celui-ci |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN108472379B (zh) | 2015-12-30 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| JP7046814B2 (ja) | 2015-12-30 | 2022-04-04 | ジェネンテック， インコーポレイテッド | タンパク質製剤のためのトリプトファン誘導体の使用 |
| CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
| EP3411396A1 (fr) | 2016-02-04 | 2018-12-12 | Curis, Inc. | Mutant smoothened et méthodes d'utilisation dudit mutant |
| US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| JP7250674B2 (ja) | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| WO2019219891A1 (fr) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Conjugué anticorps-médicament anti-muc1 |
| CN112585166A (zh) | 2018-06-23 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法 |
| CA3104147A1 (fr) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Procedes de traitement du cancer du poumon par un antagoniste de liaison d'axe pd-1, un antimetabolite et un agent a base de platine |
| AU2019319822A1 (en) | 2018-08-08 | 2021-03-18 | Genentech, Inc. | Use of tryptophan derivatives and L-methionine for protein formulation |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| WO2021257503A1 (fr) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Méthodes et compositions de traitement du cancer du sein triple négatif |
| TW202517141A (zh) | 2023-07-13 | 2025-05-01 | 新加坡商蜂鳥生物科技私人有限公司 | 生產抗體的方法 |
| TW202509209A (zh) | 2023-07-13 | 2025-03-01 | 新加坡商蜂鳥生物科技私人有限公司 | 生產抗體的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6475787B1 (en) * | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| WO1993012227A1 (fr) * | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Animaux transgeniques non humains capables de produire des anticorps heterologues |
-
2000
- 2000-03-30 DE DE60039596T patent/DE60039596D1/de not_active Expired - Lifetime
- 2000-03-30 CA CA002368734A patent/CA2368734C/fr not_active Expired - Lifetime
- 2000-03-30 AU AU34563/00A patent/AU754808B2/en not_active Expired
- 2000-03-30 AT AT00912975T patent/ATE402267T1/de not_active IP Right Cessation
- 2000-03-30 WO PCT/JP2000/002022 patent/WO2000058499A1/fr not_active Ceased
- 2000-03-30 EP EP00912975A patent/EP1167537B1/fr not_active Expired - Lifetime
- 2000-03-30 DK DK00912975T patent/DK1167537T3/da active
-
2005
- 2005-09-28 US US11/238,983 patent/US8236530B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000058499A1 (fr) | 2000-10-05 |
| US20060059575A1 (en) | 2006-03-16 |
| EP1167537A1 (fr) | 2002-01-02 |
| ATE402267T1 (de) | 2008-08-15 |
| US8236530B2 (en) | 2012-08-07 |
| DE60039596D1 (de) | 2008-09-04 |
| EP1167537B1 (fr) | 2008-07-23 |
| EP1167537A4 (fr) | 2005-05-04 |
| AU754808B2 (en) | 2002-11-28 |
| CA2368734A1 (fr) | 2000-10-05 |
| AU3456300A (en) | 2000-10-16 |
| CA2368734C (fr) | 2005-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1167537T3 (da) | Fremgangsmåde til fremstilling af et monoklonalt antistof | |
| DK0610046T3 (da) | Ekspressionsvektorer kodende for bispecifikke fusionsproteiner og fremgangsmåder til fremstilling af biologisk aktive, bispecifikke fusionsproteiner i en pattedyrscelle | |
| NZ324076A (en) | A composition comprising an immunoglobulin having an affinity constant for binding to predetermined human antigen and transgenic non-human animals capable of producing heterologous antibodies | |
| DK1583830T3 (da) | Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner | |
| DK0419858T3 (da) | Hunde-muse-heterohybridom og genfragment, som koder for den konstante region af hundeimmunglobuliner | |
| DE3278203D1 (en) | Monoclonal antibodies specific for the human transferrin receptor glycoprotein | |
| DK0380068T3 (da) | Ekspressionssystem til fremstilling af kimære monoklonale antistoffer | |
| DE59007589D1 (de) | Verfahren zur Herstellung hetero-bispezifischer Antikörper. | |
| DK0773228T3 (da) | Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse | |
| DK0613944T3 (da) | Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler | |
| Shulman et al. | Mutations affecting the structure and function of immunoglobulin M | |
| NO2007014I1 (no) | Bevacizumab (rekombinant humanisert monoklonalt antistoff) | |
| NL300335I1 (nl) | Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor | |
| DK0763128T3 (da) | Fremgangsmåde til fremstilling af heterologe bispecifikke antistoffer | |
| DK1597280T3 (da) | Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler | |
| DE60014124D1 (de) | Antikörper, die spezifisch für fullerene sind | |
| Groves et al. | Veterinary sources of nonrodent monoclonal antibodies: interspecific and intraspecific hybridomas | |
| DE3581288D1 (de) | Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen. | |
| DK1092767T3 (da) | Serinproteasespecifikke monoklonale antistoffer og anvendelse deraf | |
| ATE217888T1 (de) | Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren | |
| DE69635715D1 (de) | Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase | |
| AU2707992A (en) | Monoclonal antibodies to hepatitis c virus | |
| DK0733643T3 (da) | Membranprotein-polypeptid, som har den funktion at understøtte vækst af præ-B-celler og gen derfor | |
| JPS6447391A (en) | Monoclonal antibody and use thereof | |
| DK326289A (da) | Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden |